Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

Abroad (travel likely)RecruitingPHASE2

Conditions

Non Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing Chest Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Jinghui Wang) · jinghuiwang2006@163.com · 13683128239

Study leads

Jinghui Wang
Study Chair
Director of Research Laboratory, Beijing Chest Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Non Small Cell Lung Cancer · Pancreatic Ductal Adenocarcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Huntersville, United States · Oklahoma City, United States

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Non Small Cell Lung Cancer NSCLC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Neimeng, China · Neimeng, China

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Head and Neck Cancer · Cervical Cancer · Endometrial Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Jinan, China

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Non-Small Cell Lung Cancer · Small Cell Lung Cancer · Extrapulmonary Small Cell Cancer

Abroad (travel likely)Recruiting

Bethesda, United States